Form 4 for MCRB Seres Therapeutics, Inc.
Accepted 2024-05-17 00:00:00 ET · period of report 2024-05-14 · accession 0000950170-24-062061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-05-17 | 2024-05-15 | MCRB | von Moltke Lisa | See Remarks | S - Sale+OE | $0.94 | -939 | 19.0K | -5% | -$882.66 |
| DT | 2024-05-17 | 2024-05-15 | MCRB | von Moltke Lisa | See Remarks | M - OptEx | — | +2,968 | 20.0K | +17% | — |
| DT | 2024-05-17 | 2024-05-15 | MCRB | von Moltke Lisa | See Remarks | M - OptEx | $0.00 | -2,968 | 32.7K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-15 | S | D | 939 | $0.94 | 19,017 | D | — | — | (F3) The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.943, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-05-15 | M | A | 2,968 | — | 19,956 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
| 3 | Derivative | Restricted Stock Units | 2024-05-15 | M | D | 2,968 | $0.00 | 32,657 | D | — · — to — | 2,968 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. (F4) The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |